Business Description
Nektar Therapeutics
NAICS : 325412
SIC : 2834
ISIN : US6402681083
Share Class Description:
LTS:0UNL: Ordinary SharesCompare
Compare
Traded in other countries / regions
NKTR.USAITH.Germany0UNL.UKNKTR.Mexico IPO Date
2018-07-18Description
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.58 | |||||
| Equity-to-Asset | 0.33 | |||||
| Debt-to-Equity | 0.9 | |||||
| Debt-to-EBITDA | -0.48 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -12.69 | |||||
| Beneish M-Score | -2.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -17.9 | |||||
| 3-Year EBITDA Growth Rate | 16.5 | |||||
| 3-Year EPS without NRI Growth Rate | 30.5 | |||||
| 3-Year FCF Growth Rate | 17.2 | |||||
| 3-Year Book Growth Rate | -51.5 | |||||
| Future 3-5Y Total Revenue Growth Rate | -10.98 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.45 | |||||
| Quick Ratio | 6.14 | |||||
| Cash Ratio | 5.92 | |||||
| Days Inventory | 197.5 | |||||
| Days Sales Outstanding | 11.11 | |||||
| Days Payable | 70.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2 | |||||
| Shareholder Yield % | 5.63 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 62.53 | |||||
| Operating Margin % | -150.05 | |||||
| Net Margin % | -306.31 | |||||
| FCF Margin % | -214.68 | |||||
| ROE % | -126.07 | |||||
| ROA % | -52.95 | |||||
| ROIC % | -127.22 | |||||
| ROC (Joel Greenblatt) % | -444.45 | |||||
| ROCE % | -53.97 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.85 | |||||
| PB Ratio | 1.97 | |||||
| Price-to-Tangible-Book | 1.99 | |||||
| EV-to-EBIT | -0.23 | |||||
| EV-to-EBITDA | -0.24 | |||||
| EV-to-Revenue | 0.63 | |||||
| EV-to-FCF | -0.32 | |||||
| Price-to-Median-PS-Value | 0.27 | |||||
| Price-to-Net-Current-Asset-Value | 4.09 | |||||
| Price-to-Net-Cash | 7.12 | |||||
| Earnings Yield (Greenblatt) % | -438.97 | |||||
| FCF Yield % | -79.82 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nektar Therapeutics Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 90.122 | ||
| EPS (TTM) ($) | -1.46 | ||
| Beta | -0.14 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0 | ||
| 20-Day SMA ($) | 15.73 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 15.73 - 15.73 | ||
| Shares Outstanding (Mil) | 183.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nektar Therapeutics Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nektar Therapeutics Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nektar Therapeutics Frequently Asked Questions
What is Nektar Therapeutics(LTS:0UNL)'s stock price today?
The current price of LTS:0UNL is $15.73. The 52 week high of LTS:0UNL is $15.73 and 52 week low is $15.73.
When is next earnings date of Nektar Therapeutics(LTS:0UNL)?
The next earnings date of Nektar Therapeutics(LTS:0UNL) is 2024-05-09 Est..
Does Nektar Therapeutics(LTS:0UNL) pay dividends? If so, how much?
Nektar Therapeutics(LTS:0UNL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers